Nevro Corp.
NYSE:NVRO Rapport sur les actions
Capitalisation boursière : US$189.4m
Nevro Dividendes et rachats
Dividende contrôle des critères 0/6 Nevro n'a pas d'antécédents de versement de dividendes.
Informations clés
n/a
Rendement du dividende
-0.4%
Rendement des rachats
Rendement total pour l'actionnaire -0.4% Rendement futur des dividendes 0% Croissance des dividendes n/a Prochaine date de paiement du dividende n/a Date ex-dividende n/a Dividende par action n/a Ratio de distribution n/a
Mises à jour récentes sur les dividendes et les rachats
Afficher toutes les mises à jour
Nevro Corp. Reaffirms Earnings Guidance for the Year 2024 Nov 12
Nevro Corp. Announces New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy Oct 30
Nevro Corp. to Report Q3, 2024 Results on Nov 11, 2024 Oct 11
Consensus EPS estimates fall by 21% Aug 13
Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding Aug 11
Nevro: Not Having My Back Aug 09
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 07
Price target decreased by 25% to US$11.07 Aug 07 Nevro Revises Earnings Guidance for the Full Year 2024
Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet? Jul 16
Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024 Jul 10
Consensus EPS estimates upgraded to US$2.31 loss May 14
Price target decreased by 12% to US$16.63 May 08
Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024 May 08
Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough May 01
Nevro Corp. to Report Q1, 2024 Results on May 07, 2024 Apr 19
New minor risk - Shareholder dilution Apr 14
Nevro Corp., Annual General Meeting, May 23, 2024 Apr 13
Price target decreased by 9.5% to US$19.40 Feb 26
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way? Feb 25
Full year 2023 earnings: EPS exceeds analyst expectations Feb 22 Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024
Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024 Jan 30
There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding Jan 08
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain Nov 21
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way? Nov 16 Nevro Corp. Increases Revenue Guidance for the Full-Year 2023
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 02
Price target decreased by 7.2% to US$26.37 Oct 17
New major risk - Revenue and earnings growth Oct 16
Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023 Oct 05
Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold Sep 01
Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy Aug 17
Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system Aug 11
Consensus EPS estimates fall by 16% Aug 08 Nevro Corp. Revises Earnings Guidance for the Full-Year 2023
New minor risk - Shareholder dilution Aug 03
Price target decreased by 23% to US$28.80 Aug 02
Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry? Jul 10
Price target decreased by 8.5% to US$37.57 Jun 29
Independent Director recently bought US$172k worth of stock Jun 14
Price target decreased by 8.5% to US$38.43 Jun 08
Nevro Corp. Announces Executive Changes Jun 07
Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023 Jun 06
First quarter 2023 earnings: EPS and revenues exceed analyst expectations Apr 28
Independent Lead Director exercised options to buy US$2.9m worth of stock. Apr 17
Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings Feb 28
Nevro falls to 52-week low; down ~49% over last year Feb 22
Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023 Feb 18
Full year 2022 earnings: EPS exceeds analyst expectations Feb 18
Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains Feb 14
Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting Jan 13
Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet? Jan 13
Consensus forecasts updated Jan 11 Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023
Nevro: Opportunity Overshadowed By Weaknesses Dec 07
Price target decreased to US$47.73 Nov 16
Consensus forecasts updated Nov 09
Price target decreased to US$50.36 Nov 03
Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022 Nov 03
Boston Scientific drives rival Nevro lower after remarks on neuromodulation Oct 26
Price target decreased to US$53.91 Oct 13
Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain Oct 13
Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval Oct 13
Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022 Oct 06
Nevro gets FDA approval for Costa Rica manufacturing operations Oct 04
Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy Oct 04
Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load? Oct 02
Nevro Corp. Announces Executive Changes Sep 10
Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation Sep 07
Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy Sep 02
Consensus forecasts updated Aug 10
Second quarter 2022 earnings: EPS exceeds analyst expectations Aug 04 Nevro Corp. Revises Earnings Guidance for the Full Year 2022
Nevro and Boston Scientific Corporation Announce the Settlement of Their Ongoing Intellectual Property Litigations Aug 02
Nevro Corp. to Report Q2, 2022 Results on Aug 03, 2022 Jul 07
Nevro Corp. Announces the Complete 12-Month Results from the SENZA-PDN Randomized Controlled Trial Jul 06
Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load? Jun 17
Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery Jun 10
Price target decreased to US$69.50 Jun 07
General Counsel recently bought US$100k worth of stock May 12
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 06
Nevro Corp. Provides Earnings Guidance for the Second Quarter of 2022; Reiterates Earnings Guidance for the Year 2022 May 05 Nevro Corp., Annual General Meeting, May 26, 2022
Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de NVRO ont été stables dans le passé.
Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de NVRO ont augmenté.
Rendement des dividendes par rapport au marché Nevro Rendement des dividendes par rapport au marché
Comment le rendement du dividende de NVRO se compare-t-il à celui du marché ? Segment Rendement du dividende Entreprise (NVRO) n/a 25% du marché (US) 1.3% 25% du marché (US) 4.3% Moyenne du secteur (Medical Equipment) 1.7% Analyste prévisionnel (NVRO) (jusqu'à 3 ans) 0%
Dividende notable: Impossible d'évaluer le rendement des dividendes de NVRO par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.
Dividende élevé: Impossible d'évaluer le rendement des dividendes de NVRO par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.
Bénéfice distribué aux actionnaires
Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de NVRO afin de déterminer si les dividendes versés sont couverts par les bénéfices.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car NVRO n'a signalé aucun versement.
Découvrir des entreprises qui versent des dividendes élevés Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
